Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.71 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.71 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.71 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.71 |
| ▸ | CETP | P11597 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6348512 | 0.89 | PDK1 (0.72) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL18021884 | 0.86 | LMNA (0.58) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL2226280 | 0.86 | PDK1 (0.72) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL8140708 | 0.85 | KDM4E (0.57) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL1983314 | 0.85 | KDM4E (0.57) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL10046356 | 0.85 | KDM4E (0.57) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL7928023 | 0.85 | LMNA (0.57) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL384055 | 0.84 | LMNA (0.56) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL5706504 | 0.84 | CETP (0.71) | LMNAKDM4EALOX12PDK1PDK2 | |
| SCHEMBL6350417 | 0.84 | PDK1 (1.00) | LMNAKDM4EALOX12PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-9724381-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170049849-A9 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2017-02-23 | — | — | US | disclosed |
| CN-104520303-A | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | NAT UNIV CORP KYOTO UNIV | 2015-04-15 | — | — | CN | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| WO-2007091046-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-7151102-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20060142293-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1330442-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| WO-2002036576-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| CN-1069314-C | 2-oxoindoline derivatives | TANABE SEIYAKU CO (JP) | 2001-08-08 | — | — | CN | disclosed |
| CN-1136310-A | 2-oxoindoline derivatives | TANABE SEIYAKU CO (JP) | 1996-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | LMNA 2919/4885KDM4E 1634/4885ALOX12 2875/4885 |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | LMNA 805/4885KDM4E 2277/4885ALOX12 3755/4885 |
| US-20060142293-A1 | Phthalazinone derivatives | CBR1, CBR3, PARP2 | LMNA 345/4885KDM4E 3266/4885ALOX12 203/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | LMNA 226/4885KDM4E 2852/4885ALOX12 335/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | LMNA 4836/4885KDM4E 2294/4885ALOX12 776/4885 |
| US-20170049849-A9 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | LMNA 4153/4885KDM4E 3014/4885ALOX12 1083/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | LMNA 326/4885KDM4E 4658/4885ALOX12 3467/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | LMNA 3439/4885KDM4E 843/4885ALOX12 2381/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | LMNA 2919/4885KDM4E 1634/4885ALOX12 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.